Home - Australian Pharmacist

Call to remove homeopathy products from pharmacies

Ruth Cooper - 24 January 2019

Industry

PSA recently urged all community pharmacy banner and buyer groups to take a stand against the sale of homeopathy products by refusing to stock,...

Quitting smoking is essential, but it can take time

Chloe Hava - 2 June 2021

Industry

With more information than ever about the dangerous effects of smoking, pharmacists are there to assist patients on the road to quitting.

Children aged 6–11 years now eligible for Moderna COVID-19 vaccine

Ruth Cooper - 23 February 2022

Industry

Health experts and government officials will meet next week to discuss how to boost Australia’s child COVID-19 vaccination rates.

Australian children at risk of deadly infections

Chloe Hava - 18 September 2024

Industry

Outbreaks of whooping cough, meningococcal B and increased incidence of drug-resistant infections are placing Australian children at risk.

PSA champions equal healthcare for the LGBTIQA+ Australians

Chloe Hava - 8 February 2023

Industry

atients from LGBTQIA+ communities continue to experience poor health outcomes. How can pharmacists provide inclusive care to these patients?

Celebrating a decade of pharmacist vaccination

Chloe Hava - 8 April 2024

Industry

No longer the profession which ‘didn't touch people’, pharmacists are now one of Australia's leading vaccinators.

1...139140141...330 Page 140 of 330

7.30am	Brew and view Start the day with a strong latte; it’s non-negotiable. I’ll also usually have a quick look through my emails to get a sense of what’s coming up.
8.00am	Team alignment Connect with the team and check in on key priorities across the portfolio, including learner progress, program delivery, CPD and workforce initiatives. A lot of the focus is on aligning moving parts and making sure everything is tracking as it should.
12.00pm	Stakeholder engagement Meet with stakeholders – including health departments, partners or internal leaders – to discuss how our work supports current and evolving pharmacy roles. These conversations help to build a bridge between education and practice, ensuring what we’re doing is practical and required for pharmacists on the ground.
2.00pm	Program blueprint Spend time with the team on program design and delivery. That might be refining a workshop, reviewing content or shaping digital learning.
4.00pm	Shifting gears Pivot to more strategic work – including looking at new initiatives, thinking about what’s coming next, and how we continue to maintain and improve quality. This is usually where things start to connect across the bigger picture.
6.00pm	Evening reset Wrap up and head home. Evenings are a chance to spend time with my husband, check in on my parents in Malaysia and decompress. We chat about the day and catch up on everything that’s been going on.
8.00pm	Global growth Check emails or connect with collaborators in different time zones. I also use this time as a chance to step back and reflect on my work and where things are heading.

1989	Establishment of the SAS The SAS was established as part of the Therapeutic Goods Act to maintain access to essential medicines not listed on the ARTG, while maintaining public safety.1
2016	Legalisation of medicinal cannabis Decades of restricted research and patent difficulties reduced the commercial incentive to fund the large clinical trials needed for full TGA registration. The SAS has become the default pathway for medicinal cannabis submissions10 – particularly for chronic pain and anxiety – increasing almost 100-fold since 2018.11
2017	Introduction of SAS-C New access pathway introduced in response to TGA medical devices review.3
2021	Discontinuation of opioids used in palliative care SAS volumes increased between 2021 and 2023 following discontinuation of several oral opioid products (e.g. hydromorphone).12
2024	Restriction of vapes to therapeutic use Government policy response to address rising child and adolescent use of unregulated nicotine-containing vapes. Adult smokers seeking to use vaping as a cessation tool now use the SAS-C pathway.13

7.30am	Brew and view Start the day with a strong latte; it’s non-negotiable. I’ll also usually have a quick look through my emails to get a sense of what’s coming up.
8.00am	Team alignment Connect with the team and check in on key priorities across the portfolio, including learner progress, program delivery, CPD and workforce initiatives. A lot of the focus is on aligning moving parts and making sure everything is tracking as it should.
12.00pm	Stakeholder engagement Meet with stakeholders – including health departments, partners or internal leaders – to discuss how our work supports current and evolving pharmacy roles. These conversations help to build a bridge between education and practice, ensuring what we’re doing is practical and required for pharmacists on the ground.
2.00pm	Program blueprint Spend time with the team on program design and delivery. That might be refining a workshop, reviewing content or shaping digital learning.
4.00pm	Shifting gears Pivot to more strategic work – including looking at new initiatives, thinking about what’s coming next, and how we continue to maintain and improve quality. This is usually where things start to connect across the bigger picture.
6.00pm	Evening reset Wrap up and head home. Evenings are a chance to spend time with my husband, check in on my parents in Malaysia and decompress. We chat about the day and catch up on everything that’s been going on.
8.00pm	Global growth Check emails or connect with collaborators in different time zones. I also use this time as a chance to step back and reflect on my work and where things are heading.

1989	Establishment of the SAS The SAS was established as part of the Therapeutic Goods Act to maintain access to essential medicines not listed on the ARTG, while maintaining public safety.1
2016	Legalisation of medicinal cannabis Decades of restricted research and patent difficulties reduced the commercial incentive to fund the large clinical trials needed for full TGA registration. The SAS has become the default pathway for medicinal cannabis submissions10 – particularly for chronic pain and anxiety – increasing almost 100-fold since 2018.11
2017	Introduction of SAS-C New access pathway introduced in response to TGA medical devices review.3
2021	Discontinuation of opioids used in palliative care SAS volumes increased between 2021 and 2023 following discontinuation of several oral opioid products (e.g. hydromorphone).12
2024	Restriction of vapes to therapeutic use Government policy response to address rising child and adolescent use of unregulated nicotine-containing vapes. Adult smokers seeking to use vaping as a cessation tool now use the SAS-C pathway.13

7.30am	Brew and view Start the day with a strong latte; it’s non-negotiable. I’ll also usually have a quick look through my emails to get a sense of what’s coming up.
8.00am	Team alignment Connect with the team and check in on key priorities across the portfolio, including learner progress, program delivery, CPD and workforce initiatives. A lot of the focus is on aligning moving parts and making sure everything is tracking as it should.
12.00pm	Stakeholder engagement Meet with stakeholders – including health departments, partners or internal leaders – to discuss how our work supports current and evolving pharmacy roles. These conversations help to build a bridge between education and practice, ensuring what we’re doing is practical and required for pharmacists on the ground.
2.00pm	Program blueprint Spend time with the team on program design and delivery. That might be refining a workshop, reviewing content or shaping digital learning.
4.00pm	Shifting gears Pivot to more strategic work – including looking at new initiatives, thinking about what’s coming next, and how we continue to maintain and improve quality. This is usually where things start to connect across the bigger picture.
6.00pm	Evening reset Wrap up and head home. Evenings are a chance to spend time with my husband, check in on my parents in Malaysia and decompress. We chat about the day and catch up on everything that’s been going on.
8.00pm	Global growth Check emails or connect with collaborators in different time zones. I also use this time as a chance to step back and reflect on my work and where things are heading.

What drew you to education?

Describe your career so far.

What does your new role at PSA entail?

Tell us more about your work involving simulation and digital learning.

What are the challenges of introducing new technologies or teaching models?

Any advice for ECPs who want to shape the next generation of pharmacists?

Day in the life of Vivienne Mak, Head of Education and Training, PSA, Melbourne, Victoria

What has your career looked like so far?

Why aged care?

What are the challenges and rewards of working in this setting?

Tell us about the training program for onsite pharmacists you’re developing.

What are the next steps?

How could the ACOP program improve?

Who’s your audience?

Does placement matter?

Beyond the label

References

Regulatory obligations

Professional responsibilities

Lack of approved Product Information, CMI and clinical guidelines

Drug interactions

Entry in clinical software

Informed patient consent

Direct importation becomes sponsorship

Considering risks of treatment

The SAS timeline

References

1. Who can administer FluMist?

2. Can pharmacists co-administer vaccines?

3. Can pharmacists vaccinate interstate?

4. How do pharmacists maintain immunisation credentials?

What drew you to education?

Describe your career so far.

What does your new role at PSA entail?

Tell us more about your work involving simulation and digital learning.

What are the challenges of introducing new technologies or teaching models?

Any advice for ECPs who want to shape the next generation of pharmacists?

Day in the life of Vivienne Mak, Head of Education and Training, PSA, Melbourne, Victoria

What has your career looked like so far?

Why aged care?

What are the challenges and rewards of working in this setting?

Tell us about the training program for onsite pharmacists you’re developing.

What are the next steps?

How could the ACOP program improve?

Who’s your audience?

Does placement matter?

Beyond the label

References

Regulatory obligations

Professional responsibilities

Lack of approved Product Information, CMI and clinical guidelines

Drug interactions

Entry in clinical software

Informed patient consent

Direct importation becomes sponsorship

Considering risks of treatment

The SAS timeline

References

1. Who can administer FluMist?

2. Can pharmacists co-administer vaccines?

3. Can pharmacists vaccinate interstate?

4. How do pharmacists maintain immunisation credentials?

What drew you to education?

Describe your career so far.

What does your new role at PSA entail?

Tell us more about your work involving simulation and digital learning.

What are the challenges of introducing new technologies or teaching models?

Any advice for ECPs who want to shape the next generation of pharmacists?

Day in the life of Vivienne Mak, Head of Education and Training, PSA, Melbourne, Victoria

What has your career looked like so far?

Why aged care?

What are the challenges and rewards of working in this setting?

Tell us about the training program for onsite pharmacists you’re developing.

What are the next steps?

How could the ACOP program improve?

Who’s your audience?

Does placement matter?

Beyond the label

References

Regulatory obligations